Boehringer Ingelheim International Gmbh

Hua Medicine (shanghai) Ltd.

Hua Medicine

Guanghua Lv

Li Chen

Jun Chi Yan

Ulrich Scholz

Jin She

Xiangle Jin

Joerg Brandenburg

Jutta Kroeber

Da Deng

Juncheng Zheng

Fuxing Tang

The present disclosure provides a compound of formula (I), or an isotopically labeled product, an enantiomer, a diastereomer or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising a compound of formula (I); and use of a compound of formula (I) or a pharmaceutical composition thereof in the treatment of diabetes mellitus and related symptoms.

Prodrug of pyrrolidone derivatives as glucokinase activator

The present invention is directed to an efficient process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form of formula I wherein Rand Rindependently denote C-alkyl groups and Xdenotes an acid anion, such as the chloride, bromide, tosylate, mesylate or trifluoroacetate anion, with high quality, and a process for synthesis of EGFR tyrosine kinase inhibitors with heterocyclic quinazoline, quinoline or pyrimidopyrimidine core structure, using the acid addition salt I and activated derivatives thereof as intermediates.

[object Object]

Growing community of inventors

Shanghai, China

Guanghua Lv